Shaily Engineering Plastics Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Shaily Engineering Plastics Ltd filed with BSE on 17 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Shaily reported Q1 FY27 consolidated revenue of Rs 281 crore, up 14% year-on-year, with EBITDA of Rs 83 crore and PAT of Rs 48 crore. Healthcare revenue grew 85% to Rs 142 crore and became the largest segment, while Consumer segment revenue declined 24% to Rs 116 crore on softer demand in Europe and the US, and Industrial revenue grew 25% to Rs 23 crore. Management discussed pen injector volumes of about 9 million units in the quarter, capacity expansion plans, new Consumer Electronics and Semiconductor Tray business wins, and progress on healthcare device platforms including emergency-use, reusable and on-body injectors.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: INR281 crores (Q1 FY27)
p. 5
“Revenue for Q1 FY27 stood at INR281 crores compared with INR247 crores in Q1 FY26, registering year-on-year growth of 14%.”
Sanjay Shah, page 5 of the filed PDF · View the filing
EBITDA: INR83 crores (Q1 FY27)
p. 5
“EBITDA stood at INR83 crores from INR70 crores, reflecting a growth of 18%, while EBITDA margin improved by 120 bps to 29.7%.”
Sanjay Shah, page 5 of the filed PDF · View the filing
PAT: INR48 crores (Q1 FY27)
p. 5
“Profit after tax stood at INR48 crores compared with INR41 crores in Q1 FY26, representing a growth of 17%.”
Sanjay Shah, page 5 of the filed PDF · View the filing
PAT margin: 17.1% (Q1 FY27)
p. 5
“PAT margin improved to 17.1%, an expansion of 40 basis points year-on-year.”
Sanjay Shah, page 5 of the filed PDF · View the filing
Healthcare segment revenue: INR142 crores (Q1 FY27)
p. 4
“Segment revenue grew 85% year-on-year to INR142 crores, contributing approximately 51% of consolidated revenue and becoming our largest business segment for the quarter.”
Amit Sanghvi, page 4 of the filed PDF · View the filing
Consumer segment revenue: INR116 crores (Q1 FY27)
p. 4
“The Consumer segment reported revenue of INR116 crores during the quarter, accounting for around 41% of consolidated revenue.”
Amit Sanghvi, page 4 of the filed PDF · View the filing
Industrial segment revenue: INR23 crores (Q1 FY27)
p. 4
“The Industrial segment maintained its healthy growth trajectory with revenue increasing 25% year-on-year to INR23 crores.”
Amit Sanghvi, page 4 of the filed PDF · View the filing
Machine utilization: 50.2% (Q1 FY27)
p. 5
“Machine utilization improved to 50.2% during Q1 FY27 compared with 48.7% in Q1 FY26, reflecting a gradual improvement in capacity utilization.”
Sanjay Shah, page 5 of the filed PDF · View the filing
Exports as % of consolidated revenue: 58% (Q1 FY27)
p. 5
“Exports accounted for approximately 58% of consolidated revenue during the quarter compared with 76% in the corresponding quarter last year.”
Sanjay Shah, page 5 of the filed PDF · View the filing
Total pens/devices delivered: close to 9 million (Q1 FY27)
p. 5
“So all devices, delivery devices put together, we've done about close to 9 million in the first quarter.”
Amit Sanghvi, page 5 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Pen injector capacity — approximately 75 million pens per annum · by end of September
stated firmly by Amit Sanghvi
p. 4
“As committed earlier, our additional 25 million pen capacity is expected to become operational by end of September, taking our total installed pen injector capacity to approximately 75 million pens per annum.”
Amit Sanghvi, page 4 of the filed PDF · View the filing
Full year pen delivery volume — beyond 36 million · FY27
stated conditionally by Amit Sanghvi
p. 6
“But yes, I think we should be able to go beyond 36 million. Short answer is we should be.”
Amit Sanghvi, page 6 of the filed PDF · View the filing
Gross margin — normalized level · quarter 3
stated firmly by Sanjay Shah
p. 7
“We expect that the gross margin would come back to normalized level by quarter 3.”
Sanjay Shah, page 7 of the filed PDF · View the filing
Consumer Electronics revenue scale — $10 million revenue · 24 to 30 months
stated as an aspiration by Amit Sanghvi
p. 9
“I think 24 to 30 months is the short answer. Again, this is not a guidance. So this is what our projections look like. We think we can get to that number within 30 months.”
Amit Sanghvi, page 9 of the filed PDF · View the filing
UK subsidiary revenue — next 3 quarters
stated conditionally by Amit Sanghvi
p. 9
“It's a timing issue. It will come back over the next 3 quarters.”
Amit Sanghvi, page 9 of the filed PDF · View the filing
Consumer segment revenue — level which we did in FY26 · FY27
stated firmly by Sanjay Shah
p. 11
“So we will maintain, at a level which we did in FY26.”
Sanjay Shah, page 11 of the filed PDF · View the filing
Semiconductor Trays capex — INR5 crores
stated firmly by Sanjay Shah
p. 12
“Semiconductor Trays, I think we have mentioned that we are looking at investing about INR5 crores in our existing facility, which would meet initial requirements.”
Sanjay Shah, page 12 of the filed PDF · View the filing
Consumer Electronics facility capex — INR80 crores to INR100 crores
stated conditionally by Sanjay Shah
p. 12
“On Consumer Electronics, again, we have said that once we set up a plant down south, we would be looking at an investment of somewhere between INR80 crores to INR100 crores in that facility.”
Sanjay Shah, page 12 of the filed PDF · View the filing
Emergency use auto-injector program completion — program closure · end of '27
stated firmly by Amit Sanghvi
p. 15
“On the emergency use auto-injector, it's a program that we've been working on for roughly 18 months, and we will bring it to a closure by the end of '27.”
Amit Sanghvi, page 15 of the filed PDF · View the filing
Innovator partnership announcement — partnership announcement · next 4 to 6 quarters
stated as an aspiration by Amit Sanghvi
p. 10
“I'm quite confident that we'll get somewhere over the next 4 to 6 quarters.”
Amit Sanghvi, page 10 of the filed PDF · View the filing
Semiconductor revenue start — revenue commencement · Q4 FY27
stated firmly by Amit Sanghvi
p. 10
“Yes. That's the current Q4 Semicon revenue, yes.”
Amit Sanghvi, page 10 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
About 9 million devices delivered, with roughly 50-60% GLP-1 and the rest insulin plus other molecules.
Answered by Amit Sanghvi
Asked by Shaleen Kumar: How many pens were delivered in Q1 and what proportion was GLP-1 versus insulin?
p. 5
“You've got a bit more than insulin and GLP-1. So there is other therapies in the mix, but rough ballpark would be consider 50% to 60% GLP-1 and the rest would be insulin plus other molecule.”
Amit Sanghvi, page 5 of the filed PDF · View the filing
Speed increased by about 9%, with a further 30% jump expected once additional equipment is installed.
Answered by Amit Sanghvi
Asked by Shaleen Kumar: What is the status of the new production line that was facing setup issues?
p. 6
“We have increased speed on that line by about 9%. It still needs further improvement. So we have a plan.”
Amit Sanghvi, page 6 of the filed PDF · View the filing
Commodity and freight prices rose sharply after the war began, and pass-through timing lagged with some customers into July.
Answered by Sanjay Shah
Asked by Ritesh Shah: Why did gross margin decline sequentially despite Healthcare mix increasing?
p. 7
“So while the pass-through with some customers would have been delayed, would basically have happened between May and June.”
Sanjay Shah, page 7 of the filed PDF · View the filing
Chinese products are priced lower but are copycat technology infringing patents; management is not concerned about the pricing gap.
Answered by Amit Sanghvi
Asked by Ritesh Shah: How does Chinese competition affect GLP-1 device pricing?
p. 7
“Chinese are potentially putting their product on the market somewhere around $1.50 to $1.70.”
Amit Sanghvi, page 7 of the filed PDF · View the filing
Management said there remains a supply gap to fill and approvals remain in place, keeping confidence in guidance.
Answered by Amit Sanghvi
Asked by Ritesh Shah: Given issues with a pharma partner in Canada and Brazil, is the 36 million guidance still achievable?
p. 8
“So it's one of our partners selling. We still remain confident of the guidance.”
Amit Sanghvi, page 8 of the filed PDF · View the filing
Roughly 50-55% of capacity has commitments or indications, with the rest still being worked on.
Answered by Amit Sanghvi
Asked by Harshh Shah: What is the visibility on Abu Dhabi capacity commitments?
p. 8
“I think we've said roughly 50%, 55% is kind of commitments and indication on that kind of that capacity.”
Amit Sanghvi, page 8 of the filed PDF · View the filing
Management described work on emergency-use auto-injectors, reusable auto-injectors, and on-body injectors.
Answered by Amit Sanghvi
Asked by Nirali Gopani: What other healthcare products beyond GLP-1/insulin is Shaily working on?
p. 10
“Yes. Look, what we are working actively on first is emergency use.”
Amit Sanghvi, page 10 of the filed PDF · View the filing
Trays require extremely tight tolerances and specialized conductive plastics; fewer than a dozen global players can make them.
Answered by Sanjay Shah
Asked by Rupesh Tatiya: What is the complexity and right to win in semiconductor trays?
p. 12
“Even if you look at from a global perspective, there are less than a dozen companies who do this business globally.”
Sanjay Shah, page 12 of the filed PDF · View the filing
Feedback has been positive with very few device performance issues and no statistical decline in batch release testing.
Answered by Amit Sanghvi
Asked by Aman Vij: What has customer feedback been on pen devices in Brazil and Canada?
p. 13
“So we've not seen even a statistical decline in any of our numbers. So statistically, the performance of the device is very strong.”
Amit Sanghvi, page 13 of the filed PDF · View the filing
Management said there has been no prior statement on Cipla/inhalers and Abu Dhabi site needs to be in production by end of FY28.
Answered by Amit Sanghvi
Asked by Ritesh Shah: What is the status of the Abu Dhabi facility and Cipla inhaler program?
p. 16
“I don't think we have ever said anything about Cipla and inhalers to be very honest. We are not doing any inhalers at the moment.”
Amit Sanghvi, page 16 of the filed PDF · View the filing
Risks flagged
Geopolitical uncertainty in West Asia disrupting supply chains and commodity markets
p. 3
“The global operating environment remained challenging in the quarter with continued uncertainty arising from the geopolitical situation in West Asia and its wider impact on supply chain as well as commodity markets.”
Amit Sanghvi, page 3 of the filed PDF · View the filing
Volatility in polymer raw material prices and elevated freight costs
p. 3
“This led to volatility in key raw material prices, particularly polymers alongside logistic disruptions, container availability constraints and elevated freight costs.”
Amit Sanghvi, page 3 of the filed PDF · View the filing
Premium freight costs from airlifting material
p. 7
“And we've had some premium freight incidents where we've had to airlift material.”
Amit Sanghvi, page 7 of the filed PDF · View the filing
Softer demand in home furnishings across Europe and United States
p. 4
“Performance reflected softer demand in home furnishings across Europe and United States, our largest export markets for the business.”
Amit Sanghvi, page 4 of the filed PDF · View the filing
Chinese competitors infringing patents in the GLP-1 device market
p. 7
“Some products that the Chinese have put on the market do infringe not only our patents, but also other key suppliers globally.”
Amit Sanghvi, page 7 of the filed PDF · View the filing
Additional equipment for new production line not yet received
p. 6
“There's some additional equipment needed on the line, it's not received by Shaily yet.”
Amit Sanghvi, page 6 of the filed PDF · View the filing
Near-term demand softness in certain end markets
p. 16
“While certain end markets continue to experience near-term demand softness, our diversified business model, expanding Healthcare platforms and disciplined execution positions us well for the future.”
Amit Sanghvi, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.